Brentuximab Vedotin Monotherapy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data

Authors : Tahir Darcın, Istemi Serın, Mehmet Can Ugur, Omer Ekinci, İpek Yönal Hindilerden, Seval Akpınar, Tuba Hacıbekiroglu, Sinan Demircioğlu, Emine Gulturk, Murat Albayrak, İsmet Aydoğdu, Mehmet Sinan Dal, Mehmet Hilmi Doğu, Sinem Namdaroğlu, Ali Dogan, Meliha Nalçacı, Burhan Turgut, Semih Başcı, Fevzi Altuntaş

Pages : 186-192

Doi:10.52827/hititmedj.1320606

View : 72 | Download : 72

Publication Date : 2024-06-30

Article Type : Research

Abstract :Objective: We present data of patients with relapsed/ refractory T cell lymphomas treated with brentuximab vedotin (BV) in real-world practice. Material and Method: This study is an observational, multi-center, retrospective study. The data of patients (n=17) treated with BV alone from January 2014 until July 2020 in thirteen centers from Turkey were collected. Results: Bv was given as salvage chemotherapy to 17 patients with median age of 53. Nine (52.9%) patients had diagnosis of peripheral T cell lymphoma, not otherwise specified; 8 (47.1%) patients had anaplastic large T cell lymphoma. The median follow-up of the cohort was 20 months. Nine (52.9%) patients had complete response, 5 (29.5%) had partial response, 3 (17.6%) had progressive disease. The safety results aligned with the established profile of BV, included 2 pneumonia and 1 thrombocytopenia with grade 4. The median progression free survival of the cohort was 10 months. BV cycle and response to BV therapy were found to have an effect on the univariate analysis. Conclusion: In patients with relapsed/ refractory T cell lymphomas, BV seems to have convincing antitumor activity with favorable safety profile.
Keywords : brentuksimab vedotin, nüks, T hücreli lenfoma